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http://dx.doi.org/10.1016/j.fjs.2013.Summary Neuroleptic malignant syndrome (NMS) is a rare disorder that manifests with rigid-
ity, fever, dysautonomia, and changes in mental status. Haloperidol, an atypical antipsychotic
drug, has reportedly been used to treat agitation in patients with traumatic brain injury (TBI).
We herein present the case of a patient with TBI and agitation who, having received haloper-
idol, developed NMS. The syndrome was successfully treated with supportive care and cessa-
tion of haloperidol administration.
Copyright ª 2013, Taiwan Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Traumatic brain injury (TBI) is a common condition that
leads to significant morbidity and mortality. Approximately
33e50% of acute TBI survivors will encounter emotional
lability, such as post-traumatic agitation, characterized by
aggression, akathisia, and disinhibition.1,2 For the treatment
of agitation, multiple agents are administered, including b-
blockers, anticonvulsants, antidepressants, analgesics,
hypnotics, trazodone, amantadine, and neuroleptics.1,3 The
atypical antipsychotic haloperidol has reportedly been used
to treat agitation in patients with TBI.3,4t of Neurosurgery, Tainan
ongde Road, East District,
inet.net (H.-L. Yen).
ight ª 2013, Taiwan Surgical Asso
03.003The neuroleptic malignant syndrome (NMS) is a rare and
life-threatening disorder that manifests with rigidity, fever,
dysautonomia, and changes in mental status.5 Haloperidol
use has been associated with NMS.6 Herein, we present the
case of a patient recovering from TBI with episodes of agita-
tion, who was treated with haloperidol and consequently
developed NMS. He was successfully treated through sup-
portive care and cessation of haloperidol administration.
2. Case report
A 21-year-old man suffered a TBI after a motorcycle acci-
dent. Upon admission, he was hemodynamically stable with
a Glasgow Coma Scale (GCS) score of 7 (E1V1M5) without
focal neurological deficits. Results of a computed tomog-
raphy (CT) of the head showed a small contusion hematoma
and subarachnoid hemorrhage (Fig. 1A).ciation. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 Axial computed tomography (CT) scans upon admission (A) showing right temporal small contusion hematoma and
traumatic subarachnoid hemorrhage (arrow). (B) Scans showing hematoma resolution (arrow head) 2 days later.
Figure 2 Chronograph depicting inter-relationships between
neuroleptic drug, creatine phosphokinase (CPK) and body
temperature (BT) derangements., *Haloperidol 5 mg., **Halo-
peridol 10 mg.
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hours but with episodes of severe agitation and combat-
iveness. He was hemodynamically stable and there was no
respiratory distress. Pulse oximeter showed 99% oxygen
saturation and laboratory tests results including serum
electrolytes, blood urea nitrogen, creatine, and glucose
were normal. Haloperidol therapy was initiated for agita-
tion and combativeness after exclusion of shock, hypox-
emia, and common metabolic encephalopathy.
Intramuscular injections of haloperidol (5 mg doses) were
used as needed for agitation and combativeness. The pa-
tient was given 5 mg of haloperidol on the 1st day and 10 mg
on the 2nd day.
On in-hospital Day 2, he showed a progressive increase in
temperature to 39.8C accompanied by diaphoresis, tachy-
cardia, labile hypertension, muscle rigidity, and a reduced
level of consciousness (GCS Z 9). Brain CT demonstrated
resolution of the subarachnoid hemorrhage and clearing of
the right temporal lobe contusion (Fig. 1B). Laboratory
studies revealed creatine phosphokinase (CpK) level of
31,400 IU/L (normal: 60e190 IU/L), white blood cell count of
19,221/mL, the hemoglobin level at 14.8 g/dL, and a platelet
count of 369,000/mL (Fig. 2). Data on blood chemistry were
within normal limits with the exception of aspartate
aminotransferase at 538 U/L (normal: 0-40 U/L). Cultures of
sputum, blood, cerebrospinal fluid, and urine were all
negative. Therefore, infectious disease was ruled out.
In light of a recent history of haloperidol use combined
with the clinical presentation (hyperthermia, muscular ri-
gidity, change in the level of consciousness, and autonomic
dysfunction), his symptoms were considered to be most
consistent with NMS. The haloperidol administration was
therefore stopped and adequate hydration and external
cooling were initiated. The patient showed improvement
and recovered in 6 days.
3. Discussion
NMS is an idiosyncratic reaction characterized by changes in
the level of consciousness, muscular rigidity, hyperthermia,and autonomic dysfunction.5 It has been associated with a
number of drugs, with haloperidol being the most
frequently reported drug.6 Although the pathophysiology is
not well understood, NMS is thought to result from central
dopaminergic blockade in the basal ganglia and hypothal-
amus.7 Patients with TBI may experience decreased dopa-
minergic neurotransmission due to diffuse axonal injury,
and therefore a concomitant use of neuroleptic agents,
such as haloperidol, may cause a blockade of dopamine
receptors with the potential to provoke dyskinesia and
NMS.8
The onset of the NMS is not related to toxicity, doses, or
duration of the use of a specific agent, but can develop with
initiation of neuroleptic therapy or a change in the dose or
drug.9 Initiation of a neuroleptic agent at high dosages,
rapid titration of medication, or the use of higher potency
or the depot form of the drug can substantially increase the
risk of the NMS. In the report by Bellamy et al,6 one patient
developed NMS after receiving only 10 mg of haloperidol in
NMS in a patient with head injury 89oral form. Although this adverse effect is typically associ-
ated with higher doses, our patient developed NMS after
receiving only 15 mg of haloperidol. Other suggested risk
factors are dehydration, a previous history of NMS, physical
exhaustion, iron deficiency, extrapyramidal signs that are
resistant to treatment, and organic brain disorder.10,11
The incidence of NMS has been estimated to be
approximately 0.07e12.2% in patients treated with neuro-
leptic drugs,12 and initial symptoms can appear after the
first dose.11 In our case, the patient developed typical
clinical signs in the first 24 hours after undergoing halo-
peridol treatment. Initially, the deterioration of con-
sciousness made the differential diagnosis difficult. The
diagnosis of NMS may be difficult in the trauma victim, as
many of the signs, symptoms, and laboratory abnormalities
are not specific. Head trauma further complicates the
clinical presentation, as changes in mental status and
neurological examination may be attributed to brain injury
and its sequelae. Diagnosis generally depends on a high
index of suspicion in the absence of clinical evidence of
sepsis, central nervous system infection, or worsening brain
injury.13,14 The differential diagnosis includes malignant
hyperthermia associated with anesthesia, paroxysmal
autonomic instability with dystonia (paroxysmal sympa-
thetic storm), post-traumatic hyperthermia, heat stroke,
idiopathic acute lethal catatonia, drug interactions with
monoamine oxidase inhibitors, central cholinergic syn-
drome, and drug allergy.5,15,16 Laboratory findings in this
syndrome are characteristic but nonspecific. An increase in
CpK serum levels, which was observed in our case, has been
reported in 95% of such cases.5
The haloperidol use in those with TBI and agitation has
suggested that it may have negative effects on cognitive
and functional performance.6 Because a considerable
number of safer agents are now available, the use of neu-
roleptics in this setting is generally considered to be con-
traindicated. If TBI patients had to be treated with
haloperidol, they should be monitored closely for symptoms
of NMS. Early recognition is extremely important to reduce
mortality. The first phase of treatment is supportive ther-
apy with antipyretics, hydration, electrolyte stabilization,
and cooling blankets to reduce hyperthermia.17 Aggressive
ventilator assistance may be required and occasionally
dialysis for renal dysfunction. Discontinuation of the
neuroleptic is essential. There are no systematic clinical
trials evaluating pharmacologic treatment in NMS. The most
common medications used for the treatment of NMS are
dantrolene and bromocriptine. Amantadine and levodopa
have also been used.5,17
4. Conclusions
Development of NMS in TBI patients treated for agitation
with haloperidol should be a concern for clinicians, as these
patients may be at a greater risk for this adverse event. Theonset of symptoms inconsistent with the patient’s current
level of recovery should alert the clinician to consider
possible diagnoses other than TBI alone.References
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